Informed by nature
and guided by science
Informed
by nature
and guided
by science
Our key focus area is palliative care. In particular, Psyence is targeting the indications of anxiety and depression, and associated ailments, within the context of palliative care.
Bringing together leaders in the business of medicine and science
Our scientific and medical team are experts in neurology and the development and commercialisation of pharmaceutical products. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth.
Our News
Psyence Group Inc. Announces Results of Annual General and Special Meeting of Shareholders
Psyence Group shareholders approved all resolutions at the company’s annual general and special meeting, including matters related to the proposed GoldCoast transaction and future board appointments.
Psyence Group Inc. Announces Amendment to Amalgamation Agreement with GoldCoast Resource Corp.
Psyence Group has amended its GoldCoast amalgamation agreement, updating the proposed share consolidation formula ahead of the planned transaction.
Psyence Group Announces GoldCoast Resource Closes Second Tranche of Offering
GoldCoast has completed a brokered private placement raising $5.8 million, meeting a key condition for its proposed amalgamation with Psyence.






